肿瘤基础与临床
腫瘤基礎與臨床
종류기출여림상
JOURNAL OF BASIC AND CLINICAL ONCOLOGY
2015年
4期
302-304
,共3页
食管癌%GEMOX 方案%三维适形放疗
食管癌%GEMOX 方案%三維適形放療
식관암%GEMOX 방안%삼유괄형방료
esophageal cancer%GEMOX regimen%three-dimensional conformal radiotherapy
目的:观察 GEMOX 方案联合同步放疗治疗Ⅲ期食管癌的疗效及安全性。方法94例Ⅲ食管癌患者随机均分为2组,每组47例,对照组患者仅给予 GEMOX 方案治疗,而观察组在对照组治疗的基础上加用三维适形放疗。结果观察组有效率为82.98%,高于对照组的44.68%(χ2=16.556,P =0.001);2组白细胞减少、血小板减少及恶心呕吐发生率比较差异无统计学意义(P >0.05);观察组放射性食管炎、放射性肺炎分别为33例、7例,而对照组因未行放疗而无放射性食管炎、放射性肺炎病例(χ2=50.852,P <0.001;χ2=7.563,P =0.006)。结论 GEMOX 方案联合同步放疗治疗Ⅲ期食管癌的疗效明显优于单一 GEMOX 方案,但其导致放射性食管炎、放射性肺炎可能对患者造成一定伤害。
目的:觀察 GEMOX 方案聯閤同步放療治療Ⅲ期食管癌的療效及安全性。方法94例Ⅲ食管癌患者隨機均分為2組,每組47例,對照組患者僅給予 GEMOX 方案治療,而觀察組在對照組治療的基礎上加用三維適形放療。結果觀察組有效率為82.98%,高于對照組的44.68%(χ2=16.556,P =0.001);2組白細胞減少、血小闆減少及噁心嘔吐髮生率比較差異無統計學意義(P >0.05);觀察組放射性食管炎、放射性肺炎分彆為33例、7例,而對照組因未行放療而無放射性食管炎、放射性肺炎病例(χ2=50.852,P <0.001;χ2=7.563,P =0.006)。結論 GEMOX 方案聯閤同步放療治療Ⅲ期食管癌的療效明顯優于單一 GEMOX 方案,但其導緻放射性食管炎、放射性肺炎可能對患者造成一定傷害。
목적:관찰 GEMOX 방안연합동보방료치료Ⅲ기식관암적료효급안전성。방법94례Ⅲ식관암환자수궤균분위2조,매조47례,대조조환자부급여 GEMOX 방안치료,이관찰조재대조조치료적기출상가용삼유괄형방료。결과관찰조유효솔위82.98%,고우대조조적44.68%(χ2=16.556,P =0.001);2조백세포감소、혈소판감소급악심구토발생솔비교차이무통계학의의(P >0.05);관찰조방사성식관염、방사성폐염분별위33례、7례,이대조조인미행방료이무방사성식관염、방사성폐염병례(χ2=50.852,P <0.001;χ2=7.563,P =0.006)。결론 GEMOX 방안연합동보방료치료Ⅲ기식관암적료효명현우우단일 GEMOX 방안,단기도치방사성식관염、방사성폐염가능대환자조성일정상해。
Objective To observe the efficacy and safety of GEMOX regimen combined with concurrent radiothera-py in the treatment of stage Ⅲ esophageal cancer. Methods Ninety-four patients with stage Ⅲ esophageal cancer were randomly divided into the control group and the observation group,47 patients in each group. The patients in the two groups were treated with GEMOX regimen at the same time,the patients in the observation group were also treated with three-dimensional conformal radiotherapy. Results The effective rate in the observation group was 82. 98% ,and was 44. 68% in the control group(χ2 = 16. 556,P = 0. 001). There was no significant differences in the incidences of leu-kopenia,thrombocytopenia,nausea and vomiting between the two groups( P > 0. 05);the incidences of radiation esophagitis and radiation pneumonitis in the observation group were obviously higher than those in the control group (χ2 = 50. 852,P < 0. 001;χ2 = 7. 563,P = 0. 006). Conclusion The efficacy of GEMOX regimen combined with con-current radiotherapy for stage Ⅲ esophageal cancer is significantly better than the single GEMOX regimen,but the radi-ation esophagitis and radiation pneumonitis are observed.